Biotech Equities Technical Coverage - Orexigen Therapeutics, Novavax, Sunesis Pharma, Celldex Therapeutics, and Navidea Biopharma

LONDON, November 17, 2014 /PRNewswire/ --

Investor-Edge has initiated coverage on the following equities: Orexigen Therapeutics Inc. (NASDAQ: OREX), Novavax Inc. (NASDAQ: NVAX), Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, November 14, 2014, the NASDAQ Composite ended at 4,688.54, up 0.18%, the Dow Jones Industrial Average edged 0.10% lower, to finish the day at 17,634.74, and the S&P 500 closed at 2,039.82, up 0.02%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 777.26, down 0.83%, while the index has advanced 9.80% in the last one month. Register for your complimentary reports on these five stocks at:  

http://investor-edge.com/register

On Friday, shares in Orexigen Therapeutics Inc. recorded a trading volume of 3.74 million shares, lower than its three months average volume of 4.61 million shares. The stock ended the day at $5.65, which was 3.58% below its previous day's closing of $5.86, and registered an intraday range of $5.42 and $6.02. Orexigen Therapeutics Inc.'s shares have surged 12.10% in the previous three trading sessions, 41.96% in the last one month and 0.36% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $4.46 and $5.63, respectively. Furthermore, shares of Orexigen Therapeutics Inc. have a Relative Strength Index (RSI) of 68.51. Sign up and read the free notes on OREX at:

www.Investor-Edge.com/OREX-17Nov2014

Novavax Inc.'s stock gained 1.73%, to close Friday's session at $5.28, after oscillating between $5.09 and $5.29. The stock recorded a trading volume of 2.39 million shares, below its three months average volume of 3.77 million shares. Over the last one month and the previous three months, Novavax Inc.'s shares have advanced 12.58% and 13.79%, respectively. Additionally, from the beginning of 2014, the stock has gained 3.13%. The company's stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $4.79 is above its 200-day moving average of $4.75. Further, Novavax Inc.'s stock has an RSI of 54.80. The complimentary notes on NVAX can be downloaded as in PDF format at:

www.Investor-Edge.com/NVAX-17Nov2014

Sunesis Pharmaceuticals Inc.'s stock finished Friday's session 3.73% higher at $1.67. A total of 0.60 million shares were traded, which was much below its three months average volume of 2.22 million shares. The stock moved between $1.57 and $1.67 during the session. Although, Sunesis Pharmaceuticals Inc.'s shares have surged 34.68% in the last one month, it has lost 0.60% in the previous three trading sessions and 64.77% on YTD basis. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $5.48 is greater than its 50-day moving average of $3.79. Sunesis Pharmaceuticals Inc.'s stock has an RSI of 30.71. Register for free on Investor-Edge and access the latest research on SNSS at:

www.Investor-Edge.com/SNSS-17Nov2014

On Friday, shares in Celldex Therapeutics Inc. traded between $13.57 and $15.25 before ending the session 0.70% lower at $14.16. The stock reported a trading volume of 6.04 million shares, much above its three months average volume of 2.03 million shares. Celldex Therapeutics Inc.'s shares have declined 2.07% in the previous three trading sessions, 4.52% in the last one month and 41.51% on YTD basis. The company's stock is trading below its 50-day and 200-day moving averages of $14.49 and $16.84, respectively. Moreover, shares of Celldex Therapeutics Inc. have an RSI of 45.83. The complete research on CLDX is available for free at:

www.Investor-Edge.com/CLDX-17Nov2014

Navidea Biopharmaceuticals Inc.'s stock surged 5.45%, to close the day at an intra-day high of $1.16. The stock recorded a trading volume of 1.63 million shares, above its three months average volume of 0.71 million shares. The stock oscillated between $1.09 and $1.16 during the session. Over the last one month and since the start of this year, Navidea Biopharmaceuticals Inc.'s shares have lost 7.94% and 43.96%, respectively. However, the stock has gained 13.73% in the previous three trading sessions. The company's stock is trading below its 50-day and 200-day moving averages. The stock's 200-day moving average of $1.53 is above its 50-day moving average of $1.29. Additionally, Navidea Biopharmaceuticals Inc.'s stock has an RSI of 41.96. Free in depth research on NAVB is available at:

www.Investor-Edge.com/NAVB-17Nov2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED